The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지

Effect of Yinjinchunggan-tang(YJCGT) on Fibrogenesis in Thioacetamide(TAA)-induced Rat Liver Tissue

TAA로 유발된 간섬유화 동물모델에서 인진청간탕의 효과

  • Park, Shin-Myoung (Dept. of Internal Medicine. College of Oriental Medicine. Kyung-hee University) ;
  • Lee, Jang-Hoon (Dept. of Internal Medicine. College of Oriental Medicine. Kyung-hee University) ;
  • Kim, Young-Chul (Dept. of Internal Medicine. College of Oriental Medicine. Kyung-hee University) ;
  • Woo, Hong-Jung (Dept. of Internal Medicine. College of Oriental Medicine. Kyung-hee University)
  • 박신명 (경희대학교 한의과대학 간계내과학교실) ;
  • 이장훈 (경희대학교 한의과대학 간계내과학교실) ;
  • 김영철 (경희대학교 한의과대학 간계내과학교실) ;
  • 우홍정 (경희대학교 한의과대학 간계내과학교실)
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Yinjinchunggan-tang(YJCGT) is reported previously as having theraputic effects on hepatitis such as anti-implammatory, anti-apoptotic, anti-viral(HBV), etc. Though this prescription is not studied on its anti-fibrogenic effect, it is still expected to have the effect in the liver. Thus, this study was performed to investigate the anti-fibrogenic effect of YJCGT on thioacetamide(TAA)-induced liver fibrosis in rats. Method: Rat liver fibrosis was induced by intraperitoneal TAA injection(150mg/kg) 3 times a week for 5 weeks. After the YJCGT (YJCGT 1g/kg, YJCGT 2g/kg)-treatment, body weight, liver and spleen weights, liver function test, the complete blood count and the portal pressure were studied. In addition, gene expressions of ASMA, procollagen type Ia2, MMP2, TIMP1 and TIMP2, all of which are known to be associated with liver fibrosis, were analyzed by RT-PCR. After YJCGT (YJCGT 1g/kg, YJCGT 2g/kg) treatment, percentages of collagen in TAA-induced rat liver tissue were measured by image analyzer. Results : The body weight of the normal group increased more than that of the control and YJCGT-treated groups. The AST level of the YJCGT lg/kg-treated group significantly decreased compared to that of the control. The ALT and the GGT levels of the YJCGT 2g/kg-treated group significantly increased compared to those of the control. In the YJCGT-treated groups. WBC, RBC and Hgb elevated by TAA injection decreased but platelet count increased. In the YJCGT lg/kg-treated group, the portal pressure elevated by TAA injection significantly decreased. The significant decreases in the gene expressions of procollagen type Ia2, MMP2 and TIMP2 were observed in the YJCGT-treated groups. In histological findings. TAA injections caused severe liver fibrosis, but the YJCGT treatment significantly reduced the amounts of hepatic collagens. Conclusions: These results suggest that YJCGT has beneficial effects on the treatment of patients with liver cirrhosis as well as chronic hepatitis. Further study should be done to decide the optimal concentration of the YJCGT for the treatment of liver cirrhosis.

Keywords

References

  1. 통계청. 2007 사망 및 사망원인통계결과.
  2. Bissel DM, Maheer JJ. Hepatic fibrosis and cirrhosis. In: Zakim D, Boyer TD, ed Hepatology: A textbook of liver disease. Philadelphia: WB Saunders; 1998, p. 506-25.
  3. Gressner OA, Weiskirchen R, Gressner AM. Biomar kers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfuntion tests. Clin Chim Acta. 2007;381(2):107-13. https://doi.org/10.1016/j.cca.2007.02.038
  4. Friedman SL. Liver fibrosis-from bench to beside. J Hepatol. 2003;s38-s53.
  5. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ et al. Ralaxin inhibits effective deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut. 2001;49(4):577-8. https://doi.org/10.1136/gut.49.4.577
  6. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, Muroni MR et al. 5'-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol. 2001;34 :386-94. https://doi.org/10.1016/S0168-8278(00)00078-7
  7. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K et al. Imatinib mesylate (STI-571)attenuates liver fibrosis development in rats. Am J Physiol. 2005;288(5):907-13.
  8. 경희대학교 부속한방병원. 경희한방처방집. 서울; 트윈기획; 1997, p. 244.
  9. 우홍정. 만성B형간염에 대한 인진청간탕의 효과. 제2회 한중 학술대회 참가 논문집(간장병). 1995 :18-53.
  10. 강우성. HCV 환자에서 인진청간탕가미방투여 후 Anti-HCV 역가의 변화관찰 15예. 전국 한의학 학술대회 논문집. 1998:85-6.
  11. 김진주. 인진청간탕이 MHV-2로 유발된 마우스의 손상간에 미치는 영향. 경희대학교 대학원. 1996.
  12. 김영철, 이장훈, 우홍정. 인진청간탕의 안전성에 관한 연구. 경희한의대논문집. 1997;20(1) :57-89.
  13. 승현석, 김영철, 이장훈, 우홍정. 인진청간탕이 간보호 및 섬유화 억제에 미치는 영향. 대한한방내과학회지. 2003;24(1):21-32.
  14. 박용진, 김영철, 이장훈, 우홍정. 인진청간탕가 미방이 간세포의 증식능력에 미치는 영향. 대한한의학회지. 1998:19(1):145-64.
  15. 홍상훈, 이장훈, 우홍정. 인진청간탕가미방이 간세포활성세포주기 및 apoptosis에 미치는 영향. 대한한의학회지. 1998:19(2):337-72.
  16. 강경태, 이장훈, 우홍정. 인진청간탕가미방이 실험적 흰쥐의 간경변증에 미치는 영향. 경희한의대논문집. 1997;20(2):133-50.
  17. 김영철, 이장훈, 우홍정. 인진청간탕이 흰쥐의 간장 비실질세포의 procollagen합성 억제에 미치는 효과에 관한 연구. 대한한방내과학회지. 2003;24(4):817-25.
  18. 박상백, 김영철, 이장훈, 우홍정. 인진청간탕이 DMN 유발 간섬유화와 단백질 발현에 미치는 영향. 대한한방내과학회지. 2008;29(1):200-18.
  19. 지형준 외. 대한약전 및 대한약전외 한약규격주해. 서울: 한국메디칼인덱스사; 1998, p. 58-700.
  20. 김정룡. 소화기계질환. 서울: 일조각; 2005, p. 662-72.
  21. 주광로, 방성조, 송병철 등. 1990년대 후반 한국 성인의 B형 간염 바이러스 표지자 보유양상: 건강검진 수검자 70,347명의 성적조사. 대한소화기학회지. 1999;33:642-52.
  22. 권오상, 이창홍. 국내 만성 B형 간염 환자 자녀들의 HBV 감염율의 변화. 대한간학회지. 2001 ;7(3s):160-2.
  23. Gressner AM. Hepatic fibrogenesis: the puzzel of interacting cells, fibrogenic cytokines, regulatory loops and extracellular matrix molecules. ZeitchriftfurGastroenterologic. 1992 ;30(s):5-16.
  24. Li D, Freidman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. Journal of Gastroenterology & Hepatology. 1999;14(7):618-33. https://doi.org/10.1046/j.1440-1746.1999.01928.x
  25. Niemela O. Collagen breakdown productsas Markers of fibrosis and cirrhosis. Alcohol & Alcoholism Supplement. 1994;2:345-52.
  26. 이관식. 간섬유화 기전. 대한간학회 제3차 Postgraduate Course. 2005:9-19.
  27. Friedman SL, Molecular mechanisms of hepatic fibrosis and principles of therapy. Journal of Gastroenterology. 1997;32(3):424-30. https://doi.org/10.1007/BF02934504
  28. Blouin A, Bolender RP, Weibel ER, Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol. 1977;72 :441-55. https://doi.org/10.1083/jcb.72.2.441
  29. Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J. 1991;5 :271-7.
  30. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res. 2005;29:121S-131S. https://doi.org/10.1097/01.alc.0000189284.98684.22
  31. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol. 2005;3:95-107. https://doi.org/10.1016/S1542-3565(04)00445-8
  32. Tangkijvanich P, Yee HF Jr. Cirrhosis can we reverse hepatic fibrosis? Eur J Surg Suppl . 2002;587:100-12.
  33. Holstege A. Kollinger M, Scholmerich J. The role of fibrogenesis in the pathogenesis of portal hypertension. In: Holstege A, Hahn EG, Scholmerich J ed. Portal hypertension. Netherland: Kluwer Academic Publishers. 1955 :33-50.
  34. Schuppan D, Porov Y. Hepatic fibrosis: From bench to bedside. J Gastroenterol Hepatol. 2002;17(s):300-5. https://doi.org/10.1046/j.1440-1746.17.s3.18.x
  35. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247-50. https://doi.org/10.1074/jbc.275.4.2247
  36. Bataller R and Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
  37. Lee KS. Mechanism ofliverfibrosis. In:Kim BS, ed. Liverfibrosis. Kunja. 2000:27-42.
  38. 권영오. 간섬유화 치료의 최신지견. 대한간학회 제3차 Postgraduate Course. 2005:33-9.
  39. 신상만, 김영철, 이장훈, 우홍정. 인진이 $TGF-\beta$ 1 유도성 간섬유화에 미치는 영향. 대한한의학회지. 2001;22(3):141-55.
  40. 김성아, 우홍정, 김영철, 이장훈. 인진이 간성상 세포의 섬유화 억제에 미치는 영향. 대한한방 내과학회지. 2008;29(1):177-88.
  41. 강병기, 홍석의. 六鬱湯및 散鬱湯이 DMN및 담도결찰로 유발된 간경변증에 미치는 영향. 제2회 한중학술대회(간장병)논문집. 대한한의사협회. 1995;91-122.
  42. 이지현, 김영철, 이장훈, 우홍정. 청간해주탕이 $TGF-{\beta}$1 유도성 간섬유화에 미치는 영향. 대한 한방내과학회지. 2005;26(1):93-106.
  43. 전재현, 이장훈, 김영철, 우홍정. 청간해주탕이 알코올 유발 간섬유화와 단백질 발현에 미치는 영향. 대한한방내과학회지. 2008;29(2):469-89.
  44. 최은경, 이장훈, 김영철, 우홍정. 단삼이 간성상 세포의 섬유화 억제에 미치는 영향. 대한한방 내과학회지. 2008;29(2):229-310.
  45. Kimura K, Ando K, Ohnishi H, Ishilawa T, Kakumu S, Takemura M, et al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int Immunol. 1999;11:1491-500. https://doi.org/10.1093/intimm/11.9.1491
  46. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol. 1986;251:G176-G180.
  47. Giavarotti L, D'Almeida V, Giavarotti KA, Azzalis LA, Rodrigues L, Cravero AA, et al. Liver necrosis induced by acute intraperitoneal ethanol administration in aged rats. Free Radic Res. 2002;36:269-75. https://doi.org/10.1080/10715760290019282
  48. Jeong DH, Jang JJ, Lee SJ, Lim IK, Lee MJ, et al. Expression patterns of cell cycle-related proteins in a rat cirrhotic model induced by $CCl_4$ or thioacetamide. J Gastroenterol. 2001; 36:24-32. https://doi.org/10.1007/s005350170150
  49. Jenkins SA, Grandison A, Baxter JN, Day DW, Taylor I, Shields R, A dimethylnitrosamine -induced model of cirrhosis and portal hypertension in the rat. Jouranal of Hepatology. 1985;1 :489-99 https://doi.org/10.1016/S0168-8278(85)80747-9
  50. Xiangnong Li, Irving S. Benjamin, Barry Alexander. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. Journal of Hepatology. 2002;36 :488-93. https://doi.org/10.1016/S0168-8278(02)00011-9
  51. Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats unusefulness and reliability of this animal model. Exp Pathol. 1988;34:229-36. https://doi.org/10.1016/S0232-1513(88)80155-5
  52. Jang KT, Lee MS, Jung IP, Kim MR, Jang JJ. effect of pehtoxifylline on liver fibrosis and cell cycle related proteins in thioacetamide-induced rat cirrhosis. Korean J Hepatol. 2001;7:281-91.
  53. Perez Tamayo R. Is cirrhosis of the liver experimentally producedby $CCl_4$ andadequate model of human cirrhosis? Hepatology. 1988;3 :112-20. https://doi.org/10.1002/hep.1840030118
  54. 정규원. 만성간질환의 미세구조-간섬유조직증식과 간유동의 성상세포. 대한간학회지. 2002 ;8(3):343-53.
  55. Gianluca Svegliati Baroni, Letizia D'Ambrosia et al. Interferon -gamma Dec reases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology. 1996;23(5):1189-99. https://doi.org/10.1002/hep.510230538
  56. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102:538-49. https://doi.org/10.1172/JCI1018
  57. Friedman SL, Bansal MB. Reversal of hepatic fibrosis-factorfantasy? Hepatology. 2006;43(s) :82-8. https://doi.org/10.1002/hep.20974
  58. Friedman SL, Maher JJ, Bissell DM. Mechanism and therapy of hepatic fibrosis: report of the AASLD single topic basic research conference. Hepatology. 2000;32:1403-8. https://doi.org/10.1053/jhep.2000.20243
  59. Benyon RC, Hovell CJ, Da Gaca M, Jones EH, Iredale JP, Arthur MJ. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology. 1999;30:977-86. https://doi.org/10.1002/hep.510300431
  60. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G, Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and onoparenchymal cells of rat liver regulation by TNF-alpha and TNF-beta. J Hepatol. 1999;30:48-60. https://doi.org/10.1016/S0168-8278(99)80007-5